natgillin/translations-raw huggingface dataset:
According to a preferred embodiment of the present invention the structural loop regions of the variable domain of the immunoglobulin of murine origin comprise amino acids 6 to 20, amino acids 44 to 52, amino acids 67 to 76 and amino acids 92 to 101. The above identified amino acid regions of the respective immunoglobulins comprise loop regions to be modified. The immunoglobulin according to the invention is preferably of camel origin. 
Postupak u skladu s bilo kojim zahtjevom 19 do 21, naznačen time, da imunoglobulin obuhvaća neko od podučja strukturne petlje varijabilne domene koja sadrže modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 6 do 20, aminokiseline 44 do 52, aminokiseline 67 do 76 i aminokiseline 92 do 101, pri čemu je numeriranje prema IMGT. .
filtering at least a part of the resulting suspension S by passing at least a part of the resulting suspension S through a filtering device in order to obtain the aqueous solution comprising at least one earth alkali hydrogen carbonate, 
filtriranje barem dijela nastale suspenzije S pomoću prolaska barem dijela nastale suspenzije S kroz uređaj za filtriranje kako bi se dobila vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat, pri čemu vodena otopina koja je dobivena nakon filtriranja ima vrijednost zamućenosti manju od 1 NTU i ima koncentraciju kalcija, kao kalcijevog karbonata, od 50 do 650 mg/l,
Diverticular disease . 
Diverticular disease.
The compound of any one of claims 1 to 7 or the pharmaceutical composition of any one of claims 8-11 for use in the treatment of acute decompensated heart failure. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 1-10 za primjenu u liječenju akutne dekompenzirane srčane insuficijencije.
A method according to claim 1, wherein the axes of the first and second rotors are arranged such that a line drawn from the axis of the first rotor to the axis of the second rotor makes an angle of from 0 to 20°, below the horizontal. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su osi prvog 1 drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20", ispod vodoravne.
The antibody drug conjugate of item 9 wherein the cytotoxic agent is monomethyl auristatin E. 
PTA-11267, te pri čemu je antitijelo ili fragment istog konjugiran na monometil auristatin E (MMAE).
The functional unit 10 of the machine comprises a device 150 for supporting a capsule 200, which is inserted through a window 64 provided in the front wall 63 of the box-like body 62 . 
Funkcionalna jedinica 10 stroja sadrži uređaj 150, koji nosi kapsulu 200, koju se ubacuje kroz prozor 64 koji se nalazi na prednjoj stijenci 63 kutijastog trupa 62.
A method for diagnosing glaucoma, optic neuritis, or lattice dystrophy in a subject comprising detecting the immunospecific binding of a monoclonal antibody comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 9; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 11; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 12; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 13; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 14, or a functional part thereof, to an epitope of the amyloid protein in a sample of the subject which includes the steps of 
Postupak dijagnosticiranja glaukoma, optičkog neuritisa ili retikularne distrofije kod subjekta koji se sastoji u detektiranju imunospecifičnog vezanja monoklonskog protutijela koje sadrži CDR1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDR1 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12; CDR1 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 13; i CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 14, ili njegovog funkcionalnog dijela, na epitop u amiloidnom proteinu u uzorku iz subjekta, naznačen time što uključuje korake:
A pharmaceutical composition comprising the antibody according to claim 19 . 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema patentnim zahtjevima od 1 do 5.
A composition comprising at least one isolated IL- 23p19 antibody according to any of claims 1-10 and at least one pharmaceutically acceptable carrier or diluent. A composition according to claim 18, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Pripravak koji sadrži najmanje jedno izolirano IL-23p19 protutijelo prema bilo kojem od zahtjeva 1-5 i najmanje jedan farmaceutski prihvatljiv nosač ili otapalo, koji po potrebi nadalje sadrži jedan spoj ili polipeptid koji je odabran od detektabilnog obilježivača ili reportera, TNF antagonista, protuupalnog lijeka, kardiovaskularnog sistemskog lijeka (CV), lijeka za središnji živčani sustav (CNS), lijeka za autonomni živčani sustav (ANS), lijeka za dišne putove, lijeka za gastrointestinalni trakt (GI), hormonskog lijeka, lijeka za uspostavljanje ravnoteže tekućina ili elektrolita, hematološkog lijeka, antineoplastika, imunomodulacijskog lijeka, lijeka za oči, uši ili nazalnog lijeka, topikalnog lijeka, nutritivnog lijeka, citokina, i antagonista citokina.
The pharmaceutical composition of claim 29, wherein the additional therapeutic agent is selected from the group consisting of an HER1 inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, an mTOR inhibitor and a PI3 Kinase inhibitor. 
Farmaceutski sastav prema zahtjevu 29, naznačen time, da je dodatno terapeutsko sredstvo odabrano iz skupine koju čine: HER1-inhibitor, HER2-inhibitor, HER3-inhibitor, HER4-inhibitor, mTOR-inhibitor, i inhibitor PI3-kinaze.
irradiating the respective cable with the respective radar emission field; receiving a respective radar reflection field reflected by the respective cable, using the respective radar detector, and determining the respective kinematic parameters Q' from the respective radar reflection field, are executed for each subsequent suction tube segment, starting from a first suction tube segment that is at a first tube end (130) connected to a dredger hull (122) of the dredging vessel (120). 
HR P20140192 T1 c) primanje odgovarajućeg reflektiranog polja radara koje reflektira odgovarajući kabel, pomoću odgovarajućeg radarskog detektora, 1 d) određivanje odgovarajućih kinematičkih parametara Q* iz odgovarajućeg Teflektiranog polja radara, provode za svaki sljedeći segment usisne cijevi, počevši od prvog segmenta usisne cijevi koji se nalazi na prvom kraju cijevi (130) spojenom za trup (122) broda za jaružanje (120).
A GPS receiver (11) for receiving a current position signal from a satellite (15); characterized in that the receiving device further comprises: 
- GPS prijemnik (11) za prijem signala trenutnog položaja od satelita (15); naznačen time da prijemni uređaj nadalje sadrži:
In one embodiment the invention relates to a composition for use in preventing or treating allergy to house dust mites. 
Sastav za uporabu u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, naznačen time, što sadrži:
The process of claim 9, further comprising co-processing a non-renewable hydrocarbon feedstock (25) with the reaction effluent (28) in the hydrotreating step. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća ko-obradu neobnovljive ugljikovodične sirovine (25) s reakcijskom otpadnom tekućinom (28) u koraku hidroobrade .
detecting cleaved labeled probe, thereby determining the presence of said target nucleic acid sequence, and 
otkrivanje odcjepljene označene probe, te se tako utvrđuje prisutnost navedene ciljane sekvence nukleinske kiseline, i
The following criteria were evaluated: 
Ocjenjivani su sljedeći pokazatelji:
The fusion protein of claim 17, wherein the two single domain antibodies are a variable heavy (VH) and variable light (VL) pairing. 
Fuzijski protein prema zahtjevu 28, naznačen time što dva protutijela jedne domene imaju varijabilno teško (VH) i varijabilno lako (VL) sparivanje, te pri čemu VH i VL sparivanje veže albumin.
A system according to claim 1 wherein the length (Lc) of the cavity is between 2 m and 10 m, the distance (Hc) of the top wall (19) from the interface plane (30) being between 0.2 m and 1.5 m and the width W being between 0.5 m and 1.5 m. 
Sustav sukladno zahtjevu 1 pri čemu je duljina (Lc) šupljine između 2 m i 10 m, udaljenost (Hc) gornjeg zida (19) od ravnine sučelja (30) je između 0.2 mi 1.5 ma širina W je između 0.5mil.5m.
A compound for use according to claim 20, where the disorder is selected from schizophrenia, cognitive impairment, mild cognitive impairment (MCI), age-related cognitive decline, dementia, and Parkinson's disease. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 21, naznačen time što se poremećaj bira između shizofrenije, kognitivnog poremećaja, blagog kognitivnog poremećaja (MCI), staračkog slabljenja kognitivnih funkcija, demencije, te Parkinsonove bolesti.
motor means (96, 263) for driving said direct drive assembly and said lifter assembly; computer means (36) for activating said direct drive assembly and said lifter assembly; a control panel (13) for enabling a user to activate said apparatus; 
motorni pogonski uređaj (96, 263) za pogon uređaja za direktan pogon navedenog uređaja za dizanje; računalni uređaj (36) za aktiviranje navedenog uređaja za direktni pogon i navedenog uređaja za dizanje;
The method of claim 5, wherein said sample is a tissue biopsy, a tumor biopsy, a blood sample, or a urine sample. 
Spoj za uporabu prema zahtjevu 3, naznačen time, da navedeni uzorak je biopsija tkiva ili biopsija tumora.
The composition of claim 3, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23. The composition of claim 11, wherein the 4-1BB costimulatory signaling region of the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:17. 
(v) anti-CD19 scFv je kodiran sekvencom SEQ ID NO: 14, signalni region 4-1BB je kodiran sekvencom SEQ ID NO: 17 i signalnu domenu CD3 zeta je kodiran sekvencom SEQ ID NO: 18; ili
Lecithin and cholesterol were dissolved at 45-50° C. into a minimum amount of ethyl alcohol. 
Lecitin 1 kolesterol su otopljeni na 45-50%C u minimalnoj količini etilnog alkohola.
The method according to claim 17 or 18, further comprising the step of extending said multi-room building in a horizontal direction such that each part of the building, provided according to the method of any one of claims 1 to 16, of a first side of the corridor is aligned with a corresponding part of the building on the opposite side of the corridor. 
Postupak sukladno zahtjevu 17 ili 18, nadalje sadrži korak proširenja navedene višesobne građevine u horizontalnom smjeru na način da svaki dio građevine, omogućen sukladno postupku iz bilo kojeg od zahtjeva 1 do 16, s prve strane hodnika je poravnat s odgovarajućim dijelom građevine na suprotnoj strani hodnika.
A product for use according to claim 10, which further comprises an active compound (c), as defined in claim 5 or 6. 
Proizvedeni lijek u skladu s patentnim zahtjevom 12, naznačen time, da dodatno sadržava djelatni spoj (c) kako se definira u patentnom zahtjevu 8 ili 9.
Meanwhile, the at least one bioactive agent is selected from the group consisting of metronidazole, miconazole, ciprofloxacin, tetracycline, ketoconazole, doxycycline, zidovudine, acyclovir, penciclovir, ganciclovir, cidofovir, lamivudine, zalcitabine, valacyclovir, stavudine, ritonavir, indinavir, didanosine, dideoxyadinosine, clotrimazole, terbinafine, chlorhexidine, mafenide, clindamycin, paclitaxel, mitomycin, 5-fluorouracil, leflunamide, enfuvirtide, gemcitabine, erythromycin, ofloxacin, ceftriaxone, and cefpodoxime. 
Uređaj u vidu višekomponentne mikrobicidne kontraceptivne intravaginalne prstenaste mrežice u skladu s patentnim zahtjevom 3, naznačen time što najmanje jedno bioaktivno sredstvo se bira iz skupine koju čine metronidazol, mikonazol, ketokonazol, flukonazol, tobramicin, rapamicin, amfotericin, 5-fluorcitozin, ciprofloksacin, tetraciklin, doksiciklin, zidovudin, aciklovir, penciklovir, ganciklovir, cidofovir, lamivudin, zalcitabin, valaciklovir, stavudin, ritonavir, indinavir, didanozin, dideoksiadinozin, klotrimazol, terbinafin, klorheksidin, mafenid, klindamicin, paklitaksel, mitomicin, 5-fluoruracil, leflunomid, enfuvirtid, gemcitabin, eritromicin, ofloksacin, ceftriakson, te cefpodoksim.
The amount of resin represents from 1 to 10%, preferably at most 5%, by weight of solid matter relative to the total weight of the insulation product. 
Proizvod sukladno zahtjevima 1 do 7, naznačen time da smola predstavlja 1 do 10 % težine čvrste tvari u ukupnoj težini izolacijskog proizvoda.
wherein said compound of Formula I is for administration before said one or more ancillary therapeutic component(s). 
pri čemu je navedeni spoj s Formulom I za primjenu prije navedene ne ili više pomoćnih terapijskih komponenti.
A facility according to any one of the claims 9 to 11, comprising a flashing section having a liquid inlet in fluid communication with a liquid outlet of the urea synthesis section, a liquid outlet in fluid communication with a liquid inlet of the carbamate recirculation section, and a gas-flow line to the condensation system. 
Pogon prema jednom od zahtjeva 9 do 11, koji se sastoji od dijela za ohlađivanje s ulaznim otvorom povezanim tekućinom s izlaznim otvorom dijela za sintezu uree, izlaznog otvora povezanog tekućinom s ulaznim otvorom dijela za optjecanje karbamata i linije za protok plina do kondenzacijskog sustava.
The base unit can be equipped with seals on the upper and/or lower periphery of the outer wall 16 as described above. 
Osnovnu jedinicu se može opremiti s brtvama na gornjem i/ili na donjem rubu vanjske stijenke 16, kao što je gore opisano.
The valve (10) of claim 9, wherein the satin weave pattern comprises warp fibers made of non-shape memory material and weft fibers made of the shape memory material. 
osnovni obrazac tkanja koji sadrži vlakna napravljena od memorijskog materijala koji nema memoriju oblika; i satenski obrazac tkanja koji sadrži vlakna napravljena od materijala sa memorijom oblika.
an error counter (21a-21d) having an input connected to the output of said EXOR logic gate (20a-20d); and 
- - brojač grešaka (21a-21d) koji ima ulaz povezan na izlaz navedenih isključivih ILI logičkih vrata (20a-20d); 1
Plasma glucose, triglyceride, and hematocrit levels along with body weight are measured before the study began (day 0) and at the end of the study (day 7). 
Razine glukoze, triglicerida, te hematokrit u plazmi, kao i tjelesnu težinu, mjeri se prije početka (0. dan), te na kraju ispitivanja (7. dan).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
The method according to aspect 13 or 14 wherein the first solvent is a primary alcohol, a secondary alcohol, or a tertiary alcohol. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time, da je prvo otapalo primarni alkohol, sekundarni alkohol ili tercijarni alkohol.
a determining unit, configured to determine a sending format of the control channel of the carrier, and calculate the transmitting power of the control channel according to the sending format; 
jedinicu za određivanje (5021), podešenu za određivanje formata slanja kontrolnog kanala nosača, te za računanje snage odašiljanja kontrolnog kanala prema formatu koji se šalje;
The method of claim 1 wherein the step of the forming the FRC includes forming a formation FRC in the opposing first and second formation sections coupled to opposite ends of the confinement chamber and accelerating the formation FRC from the first and second formation sections towards the mid-plane of the chamber where the two formation FRCs merge to form the FRC. 
Sustav prema zahtjevu 6, naznačen time, da dodatno obuhvaća komplet zrcalnih utičnih zavojnica koje su omotane oko tjesnaca (442) u prolaznom kanalu između svakog od prvog i drugog tvorbenog dijela (200) te prvog i drugog preusmjerivača (300).
The mixture was heated at reflux for one hour. 
Smjesa je zagrijavana refluksiranjem tijekom jednog sata.
Such solid or semi-solid cosmetic emollients include glyceryl dilaurate, hydrogenated lanolin, hydroxylated lanolin, acetylated lanolin, petrolatum, isopropyl lanolate, butyl myristate, cetyl myristate, myristyl myristate, myristyl lactate, cetyl alcohol, isostearyl alcohol and isocetyl lanolate. 
Takvi kruti ili polu-kruti kozmetički emolijenti uključuju gliceril dilaurat, hidrogenirani lanolin, hidroksilirani lanolin, acetilirani lanolin, vazelin, izopropil lanolat, butil miristat, cetil miristat, miristil miristat, miristil laktat, cetil alkohol, izostearil alkohol 1 izocetil lanolat.
Formulations with increasing amount of RME was applied on steel surface and cured under normal curing conditions (air temperature of 300°C, 37 seconds, final substrate temperature of 240°C). 
Formulacija s povećanom količinom RME-a nanesena je na čeličnu površinu i otvrdnuta pod normalnim uvjetima otvrdnjavanja (temperatura zraka 300%C, 37 sekundi, krajnja temperatura podloge 240%C).
Examples of hormonal agents include leuprorelin, goserelin, triptorelin, buserelin, tamoxifen, toremifene, flutamide, nilutamide, cyproterone bicalutamid anastrozole, exemestane, letrozole, fadrozole medroxy, chlormadinone, megestrol, other LHRH agonists, other anti-estrogens, other anti-androgens, other aromatase inhibitors, and other progestagens. 
Oblik prema zahtjevu 33 ili 34, gdje se taj hormon izabire između leuprorelina, goserelina, triptorelina, buserelina, tamoksifena, toremifena, flutamida, nilutamida, ciproterona, bikalutamida, anastrozola, eksemestana, letrozola, fadrozola, medroksi, klormadinona, megestrola, drugih LHRH agonista, drugih anti-estrogena, drugih anti-androgena, drugih inhibitora aromataze i drugih progestagena.
The pharmaceutical composition of embodiment 16, wherein the drug particles have an average particle size of less than about 400 µm, the rapidly dispersing granules have an average particle size of less than about 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than about 30 µm. The pharmaceutical composition of embodiment 16, wherein the drug particles have an average particle size of less than about 4 µm, the rapidly dispersing granules have an average particle size of less than about 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than about 30 µm. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 10, naznačeno time da čestice lijeka imaju prosječne veličinu čestica manje od 400 um, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manje od 300 um, i sredstvo za raspadanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um; ili pri čemu je budezonid ili njegov solvat ili estar raspoređen po površini ekscipijensa, dok brzo raspršujuće granule imaju prosječnu veličinu čestica manju od 300 um, i sredstvo za raspršivanje i šećerni alkohol i/ili saharid imaju prosječnu veličinu čestica manju od 30 um.
coating the particles obtained in step (2) with a layer of a sustained release polymer. 
(3) oblaganja čestica dobivenih u koraku (2) slojem polimera za produljeno otpuštanje.
the compound fenpropidin. 
(B) spoj fluopiram.
Specifically, the second grip means are pivotally connected to the support structure 2, in order to be able to rotate between said operative configuration and said resting configuration. 
Naročito je drugo sredstvo za zahvaćanje spojeno s nosivom konstrukcijom 2, i to na takav način da se može zakretati, kako bi se na taj način sredstvo za zahvaćanje moglo zakretati između navedenog radnog položaja i navedenog položaja mirovanja.
The method of claim 1, wherein the endogenous 11-cis-retinal deficiency is associated with Age-Related Macular Degeneration, Leber Congenital Amaurosis (LCA), Retinitis Punctata Albesciens, Congenital Stationary Night Blindness, Fundus Albipunctatus, or Retinitis Pigmentosa. 
Upotreba iz patentnog zahtjeva 17 ili 18, naznačena time, da je deficijencija endogenog 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnim amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
The response in the presence of the antagonist was calculated as a percentage of the control response to capsaicin or low pH and was plotted against the concentration of antagonist. 
Reakcija u prisutnosti antagonista izračunata je kao postotak od kontrolne reakcije na kapsaicin ili na nisku vrijednost pH i to je grafički prikazano u ovisnosti o koncentraciji antagonista.
A preferred, but non-limitative example of a process of the invention implementing such an additional treatment agent is a process implementing a siloxane, and preferably a polydimethylsiloxane (PDMS). 
Postupak prema zahtjevu 23, naznačen time da je dodatno sredstvo za obradu siloksan, te poželjnije polidimetilsiloksan (PDMS).
The process of claim 15, wherein the temperature of step c) is defined to be the target inlet air temperature and wherein the curing step starts when the inlet air temperature reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the inlet air temperature subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the inlet air temperature drops below said temperature in a parabolic or triangular temperature profile. 
Postupak prema zahtjevu 15, naznačen time da je temperatura u koraku c) definirana kao ciljana ulazna temperatura zraka i gdje korak stvrdnjavanja započinje kada ulazna temperatura zraka dostigne navedenu temperaturu i gdje korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te ulazna temperatura zraka naknadno pada ispod navedene temperature za više od oko 10 "C ili ispod oko 62 *C, u tr> to HR P20090688 T1 temperaturnom profilu nalik platou ili kada ulazna temperatura pada ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
External Phase Lactose monohydrate 
Vanjska faza laktoza monohidrat
The blister pack according to Claim 19, in which said second layer (8B) comprises a layer of aluminium. 
Blister pakiranje prema 17. zahtjevu, naznačeno time da navedeni drugi sloj (88) sadrži aluminijski sloj.
The process of clause 33, wherein from about 30 to about 1000 ppm by weight of ferric chloride is maintained in the reaction zone of step (iii). The process of clause 33, wherein from about 30 to about 20000 ppm by weight of ferric chloride is maintained in the reaction zone of step (iv). 
Postupak prema zahtjevu 16, gdje se od 10 do 1090 ppm po težini željezovog(III) klorida održava u reakcijskoj zoni u koraku (iii) ili se od 10 do 20000 ppm po težini željezovog(III) klorida održava u reakcijskoj zoni u koraku (iv).
heating the solution resulting from step (i) to a temperature of about 80° C. at about 15 minutes; 
(1i) zagrijavanje otopine dobivene u koraku (1) do temperature od 80%C kroz 15 minuta;
is selected from the group consisting 
Rsje odabran iz skupine koja sadrži